Computational design and validation of siRNAs to knock down the Australian Bat Lyssavirus glycoprotein gene

Computational design and validation of siRNAs to knock down the Australian Bat Lyssavirus glycoprotein gene | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Short Report Computational design and validation of siRNAs to knock down the Australian Bat Lyssavirus glycoprotein gene Velan This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9431087/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The Australian bat lyssavirus (ABLV) is an enzootic Australian virus that causes encephalitis in humans. Though it is 100% fatal after symptoms appear, much like rabies, it is relatively rare, as only 5 cases and mortalities have ever been recorded. When post-exposure prophylaxis immunoglobulin is not given, there are no treatments that can prevent mortality. siRNAs are double-stranded RNAs that can perform gene knockdown and hold the potential to treat ABLV infections in humans. This in-silico study was able to design 10 siRNA sequences using siDirect, which were then validated using various in-silico methods, showing great potential for causing gene knockdown of the ABLV glycoprotein gene. Further in-vitro and in vivo studies are required on this topic to further investigate the viability of siRNA in treating lyssavirus infections such as the ABLV. Computational Biology Infectious Diseases siRNA Lyssavirus computational biology infectious disease oligonucleotide therapies Full Text Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9431087","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Short Report","associatedPublications":[],"authors":[{"id":623880372,"identity":"509470f2-84c4-468f-9c31-86cc316ce073","order_by":0,"name":"Velan","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+ElEQVRIiWNgGAWjYFAC5gYQmcAGYdgAMWPjAfxaGGFawIw0sAhxWqCMw2AxvFoMjjc2fi7MqcvjY29sfPi17bzd2vbDQFtqbKJxajlzsFl65rbDxWw8B5uNZdtuJ287kwjUciwttwGHFskZiQ3SvNsOJLZJJLZJSwK1mB0AamFsOIxby/yHzb95t9XBtJxLNjv/EL8WfgnGNqAtzGAtkh/bDtiZ3SBgCz9PYps1L8wvDOeSE8xuAG1JwOMXNvbDh28DHZYn39588OGPMjt7s/PpDx98qLHBqQUFMPOyMSSCVSYQoxwEGH/8YbAnVvEoGAWjYBSMHAAAl3pmNUi4A6sAAAAASUVORK5CYII=","orcid":"https://orcid.org/0009-0006-1926-8244","institution":"University of Toronto","correspondingAuthor":true,"prefix":"","firstName":"","middleName":"","lastName":"Velan","suffix":""}],"badges":[],"createdAt":"2026-04-15 21:16:47","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-9431087/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9431087/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":107481177,"identity":"8c5b3370-ce2b-44d9-ba81-86d5fdb3d913","added_by":"auto","created_at":"2026-04-22 02:16:25","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":157043,"visible":true,"origin":"","legend":"","description":"","filename":"ComputationaldesignandvalidationofsiRNAstoknockdowntheAustralianBatLyssavirusglycoproteingene1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9431087/v1_covered_cc01e278-2fec-473a-ad27-bff5e4a423cb.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eComputational design and validation of siRNAs to knock down the Australian Bat Lyssavirus glycoprotein gene\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"University of Toronto","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"siRNA, Lyssavirus, computational biology, infectious disease, oligonucleotide therapies","lastPublishedDoi":"10.21203/rs.3.rs-9431087/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9431087/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe Australian bat lyssavirus (ABLV) is an enzootic Australian virus that causes encephalitis in humans. Though it is 100% fatal after symptoms appear, much like rabies, it is relatively rare, as only 5 cases and mortalities have ever been recorded. When post-exposure prophylaxis immunoglobulin is not given, there are no treatments that can prevent mortality. siRNAs are double-stranded RNAs that can perform gene knockdown and hold the potential to treat ABLV infections in humans. This in-silico study was able to design 10 siRNA sequences using siDirect, which were then validated using various in-silico methods, showing great potential for causing gene knockdown of the ABLV glycoprotein gene. Further in-vitro and in vivo studies are required on this topic to further investigate the viability of siRNA in treating lyssavirus infections such as the ABLV.\u003c/p\u003e","manuscriptTitle":"Computational design and validation of siRNAs to knock down the Australian Bat Lyssavirus glycoprotein gene","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-04-17 04:35:08","doi":"10.21203/rs.3.rs-9431087/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d51db890-d441-4c31-a286-f73c2d13a758","owner":[],"postedDate":"April 17th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":66398753,"name":"Computational Biology"},{"id":66398754,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2026-04-17T04:35:08+00:00","versionOfRecord":[],"versionCreatedAt":"2026-04-17 04:35:08","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9431087","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9431087","identity":"rs-9431087","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}